Intercept Pharmaceuticals Inc. (ICPT)
$19.00
$0.00 (0.00%)As on 14-Nov-2023 09:30EDT
Market cap
$795 Mln
Revenue (TTM)
$318 Mln
P/E Ratio
--
P/B Ratio
44.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-59 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.6
-
Debt to Equity
3.1
-
Book Value
$--
-
EPS
$-1.4
-
Face value
--
-
Shares outstanding
41,826,000
10 Years Aggregate
CFO
$-1,602.26 Mln
EBITDA
$-1,819.15 Mln
Net Profit
$-2,405.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
| 53.6 | 4.4 | 81.3 | 17.9 | -20.5 | -28.4 | -9.6 |
|
BSE Sensex*
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
| -24.1 | -34.0 | -80.1 | 22.9 | 72.0 | -46.2 | -27.3 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Intercept Pharmaceuticals (ICPT)
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a... farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A.. Read more
-
Pres, CEO & Director
Mr. Jerome B. Durso
-
Pres, CEO & Director
Mr. Jerome B. Durso
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Intercept Pharmaceuticals (ICPT)
What is the current share price of Intercept Pharmaceuticals Inc (ICPT) Today?
The share price of Intercept Pharmaceuticals Inc (ICPT) is $19.00 (NASDAQ) as of 14-Nov-2023 09:30 EDT. Intercept Pharmaceuticals Inc (ICPT) has given a return of -20.54% in the last 3 years.
What is the current PB & PE ratio of Intercept Pharmaceuticals Inc (ICPT)?
Since, TTM earnings of Intercept Pharmaceuticals Inc (ICPT) is negative, P/E ratio is not available.
The P/B ratio of Intercept Pharmaceuticals Inc (ICPT) is 44.19 times as on 20-Nov-2023, a 986 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
4.45
|
5.51
|
|
2021
|
-3.32
|
-2.62
|
|
2020
|
-2.51
|
-4.89
|
|
2019
|
-10.39
|
78.79
|
|
2018
|
-9.67
|
156.34
|
What is the 52 Week High and Low of Intercept Pharmaceuticals Inc (ICPT)?
The 52-week high and low of Intercept Pharmaceuticals Inc (ICPT) are Rs -- and Rs -- as of 08-Jun-2026.
What is the market cap of Intercept Pharmaceuticals Inc (ICPT)?
Intercept Pharmaceuticals Inc (ICPT) has a market capitalisation of $ 795 Mln as on 20-Nov-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Intercept Pharmaceuticals Inc (ICPT)?
Before investing in Intercept Pharmaceuticals Inc (ICPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.